Skip to main content

Treatment Clinical Trials for Breast Neoplasm

Review the breast neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 326-350 of 449

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) cells with or without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Naxitamab and Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Stereotactic Radiation with Sacituzumab Govitecan and Zimberelimab for the Treatment of Patients with Metastatic Triple Negative Breast Cancer with Brain Metastases, TARGET-TNBC Trial
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status: Active
Location: 2 locations
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Muse Magnetic Resonance Guided Focused Ultrasound System for the Treatment of Breast Cancer
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Pre-operative Radiation Therapy for the Treatment of Females with Early Stage Biologically Favorable Breast Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cannabidiol for the Treatment of Stage I-III Breast Cancer in Patients Awaiting Surgical Resection
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Focused Ultrasound with Low-Dose Gemcitabine to Increase Immune Control in Patients with Stage I-III Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Breast Radiotherapy (SABER) for the Treatment of Hormone Receptor Positive HER2 Negative Early Stage Breast Cancer
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
A Combined Vaccine (MVF-HER-2 [597-626] and MVF-HER-2 [266-296]) for the Treatment of Metastatic or Unresectable Breast or Gastrointestinal Cancer
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Chimeric HER2 B-cell Peptide Vaccine Emulsified in Montanide ISA 720 for the Treatment of High-Risk HER2 Positive Breast Cancer
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Genetically Engineered Cells (iC9-CAR.B7-H3 T cells) for the Treatment of Patients with Relapsed or Refractory Triple Negative Breast Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Dendritic Cell Vaccine in Combination with Elacestrant for the Treatment of ESR1-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas